


=> d 13  
L3 HAS NO ANSWERS  
L3 STR



VAR G1=O/N  
VAR G2=2/1/6/5  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1  
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

=> s 13 ful  
FULL SEARCH INITIATED 10:49:00 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 68625 TO ITERATE

100.0% PROCESSED 68625 ITERATIONS  
SEARCH TIME: 00.00.02

294 ANSWERS

L5 294 SEA SSS FUL L3

=> fil caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
157.10 157.31

FILE 'CAPLUS' ENTERED AT 10:49:08 ON 23 FEB 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2004 VOL 140 ISS 9  
FILE LAST UPDATED: 22 Feb 2004 (20040222/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15

L6 14 L5

=> S 16 and py<2000  
19722118 PY<2000  
L7 2 L6 AND PY<2000

=>

=> d bib abs hitstr 1-2

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1997:594631 CAPLUS

DN 127:262677

TI Methods of treating or preventing sleep apnea using di- and trisubstituted benzimidazoles

IN Gitter, Bruce D.; Iyengar, Smriti

PA Eli Lilly and Co., USA; Gitter, Bruce D.; Iyengar, Smriti

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE


PI	WO 9731635	A1	19970904	WO 1997-US3113	19970226 <--	
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU	9721390	A1	19970916	AU 1997-21390	19970226 <--
	US	6030992	A	20000229	US 1998-142026	19980827
PRAI	US 1996-12665P	P	19960301			
	WO 1997-US3113	W	19970226			

OS MARPAT 127:262677

GI



I



II

AB This invention provides methods for the treatment or prevention of sleep apnea (no data) using substituted benzimidazoles I [R1, R2 = H, alkyl, alkoxy, (un)substituted heterocyclyl, phenylalkoxy, phenylalkylenideny, heterocyclylalkoxy, etc.; R3 = H, NO2, alkanoyl, alkyl, alkoxy, halo, (un)substituted amino, heterocyclyl, heterocyclylalkoxy, hydroxyalkyl,


etc.; provided that both of R1 and R2 cannot be H] and their pharmaceutically acceptable salts or solvates. Examples include 174 syntheses of I, including both the preferred amine-containing target compds., and other compds. I serving primarily as intermediates. Eleven pharmaceutical formulations are also given. For instance, the intermediate compound I·HCl [R1 = 3,4,5-trimethoxyphenyl; R2 = CH<sub>2</sub>Ph; R3 = 6-OH] (prepared in 3 steps from 4-amino-3-nitrophenol) was etherified with 4-(2-chloroethyl)morpholine-HCl using K<sub>2</sub>CO<sub>3</sub> in acetone to give a preferred title compound, II.

IT 196105-53-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug and/or intermediate; preparation of benzimidazoles for treatment or prevention of sleep apnea)

RN 196105-53-0 CAPLUS

CN Carbamic acid, butyl[2-(4-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:737335 CAPLUS

DN 123:143893

TI Preparation of benzimidazoles as prostacyclin PG12 mimetics.

IN Kuhnke, Joachim; Eckle, Emil; Thierauch, Karl-Heinz; Verhallen, Peter

PA Schering A.-G., Germany

SO Ger. Offen., 10 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4330959	A1	19950316	DE 1993-4330959	19930909 <--
	WO 9507263	A1	19950316	WO 1994-EP2948	19940906 <--


W: JP, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI DE 1993-4330959 19930909

OS MARPAT 123:143893

GI




AB Title compds. [I; R<sub>1</sub>, R<sub>2</sub> = (substituted) Ph, heteroaryl; R<sub>3</sub>, R<sub>4</sub> = H, halo, alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, carboxyl, alkoxy carbonyl, NO<sub>2</sub>, amino, etc.; (A = bond) O or S-interrupted alkylene, alkynylene, alkynylene, Q1; n = 1-4; R<sub>5</sub> = carboxyl, SO<sub>3</sub>H, PO<sub>3</sub>H<sub>2</sub>, tetrazolyl], were prepared as PG12 mimetics and TXA<sub>2</sub>/PGH<sub>2</sub> antagonists useful in treating thrombosis, arteriosclerosis, and hyperlipidemia (no data). Thus, 1,2-diphenyl-1H-benzimidazol-6-ol, MeO<sub>2</sub>CH<sub>2</sub>Br, and K<sub>2</sub>CO<sub>3</sub> were refluxed 3 h in acetone to give Me [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]acetate, which was stirred 24 h in a mixture of aqueous NaOH, THF, and MeOH to give [(1,2-diphenyl-1H-benzimidazol-6-yl)oxyl]acetic acid.

IT 166396-70-9P 166396-71-0P 166396-72-1P  
166396-73-2P 166396-74-3P 166396-75-4P  
166396-76-5P 166396-77-6P 166396-78-7P  
166396-79-8P 166396-80-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benzimidazoles as prostacyclin PG12 mimetics)


RN 166396-70-9 CAPLUS

CN Acetic acid, [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-71-0 CAPLUS

CN Pentanoic acid, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-72-1 CAPLUS

CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-73-2 CAPLUS


CN Pentanoic acid, 5-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-74-3 CAPLUS  
CN Hexanoic acid, 6-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-  
(9CI) (CA INDEX NAME)




RN 166396-75-4 CAPLUS  
CN Pentanoic acid, 5-[(1-[4-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl)oxy]-  
(9CI) (CA INDEX NAME)




RN 166396-76-5 CAPLUS  
CN Pentanoic acid, 5-[(1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-  
(9CI) (CA INDEX NAME)




RN 166396-77-6 CAPLUS  
CN Hexanoic acid, 6-[(1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-  
(9CI) (CA INDEX NAME)




RN 166396-78-7 CAPLUS  
CN Pentanoic acid, 5-[[1-[3-[[4-chlorophenyl]sulfonyl]amino]phenyl]-2-phenyl-  
1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 166396-79-8 CAPLUS  
 CN Pentanoic acid, 5-[(1-[3-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]— (9CI) (CA INDEX NAME)



RN 166396-80-1 CAPLUS  
 CN Pentanoic acid, 5-[(1-[4-[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]— (9CI) (CA INDEX NAME)




IT 166396-81-2P 166396-82-3P 166396-83-4P  
 166396-84-5P 166396-85-6P 166396-86-7P  
 166396-87-8P 166396-90-3P 166396-91-4P  
 166396-92-5P 166396-93-6P 166396-94-7P  
 166396-95-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzimidazoles as prostacyclin PG12 mimetics)


RN 166396-81-2 CAPLUS  
 CN Acetic acid, [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]—, methyl ester (9CI)  
 (CA INDEX NAME)




RN 166396-82-3 CAPLUS  
 CN Pentanoic acid, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]—, methyl ester (9CI) (CA INDEX NAME)




RN 166396-83-4 CAPLUS  
 CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, ethyl ester  
 (9CI) (CA INDEX NAME)




RN 166396-84-5 CAPLUS  
 CN Pentanoic acid, 5-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-85-6 CAPLUS  
 CN Hexanoic acid, 6-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-86-7 CAPLUS  
 CN Pentanoic acid, 5-[(1-(4-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 166396-87-8 CAPLUS  
CN Pentanoic acid, 5-[(1-[4-(acetylaminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-90-3 CAPLUS  
CN Pentanoic acid, 5-[(1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-91-4 CAPLUS  
CN Hexanoic acid, 6-[(1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-92-5 CAPLUS  
CN Pentanoic acid, 5-[(1-(3-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-93-6 CAPLUS  
CN Pentanoic acid, 5-[(1-[3-[[4-chlorophenyl]sulfonyl]aminophenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-94-7 CAPLUS  
CN Pentanoic acid, 5-[1-[3-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-95-8 CAPLUS  
CN Pentanoic acid, 5-[1-[4-[[[4-chlorophenyl]sulfonyl]aminophenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-71-0 CAPLUS  
CN Pentanoic acid, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy] - (9CI) (CA INDEX NAME)




RN 166396-72-1 CAPLUS  
CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy] - (9CI) (CA INDEX NAME)




RN 166396-73-2 CAPLUS  
CN Pentanoic acid, 5-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy] - (9CI) (CA INDEX NAME)




RN 166396-74-3 CAPLUS  
CN Hexanoic acid, 6-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy] - (9CI) (CA INDEX NAME)




RN 166396-75-4 CAPLUS  
CN Pentanoic acid, 5-[(1-[4-(acetylaminophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy] - (9CI) (CA INDEX NAME)




RN 166396-82-3 CAPLUS  
CN Pentanoic acid, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester  
(9CI) (CA INDEX NAME)




RN 166396-83-4 CAPLUS  
CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, ethyl ester  
(9CI) (CA INDEX NAME)




RN 166396-84-5 CAPLUS  
CN Pentanoic acid, 5-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-,  
methyl ester (9CI) (CA INDEX NAME)




RN 166396-85-6 CAPLUS  
CN Hexanoic acid, 6-[(1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl)oxy]-,  
methyl ester (9CI) (CA INDEX NAME)




CN 400396-78-7 CAPLUS  
CN Pentanoic acid, 5-[{1-[3-[(4-chlorophenyl)sulfonyl]amino]phenyl}-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 166396-79-8 CAPLUS  
CN Pentanoic acid, 5-[{1-[3-(acetylamino)phenyl}-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 166396-80-1 CAPLUS  
CN Pentanoic acid, 5-[{1-[4-[(4-chlorophenyl)sulfonyl]amino]phenyl}-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)



IT 166396-81-2P 166396-82-3P 166396-83-4P  
166396-84-5P 166396-85-6P 166396-86-7P  
166396-87-8P 166396-90-3P 166396-91-4P  
166396-92-5P 166396-93-6P 166396-94-7P  
166396-95-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

RN 166396-81-2 CAPLUS  
CN Acetic acid, [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester (9CI)  
(CA INDEX NAME)

